Faculty

Back to Index
Paul Stephen Aisen, MD
Professor of Neurology
Director, Alzheimer's Therapeutic Research Institute
Neurology
ATRI 9860 Mesa Rim Road Health Sciences Campus San Diego

Overview

Paul Aisen, M.D., has been appointed founding director of USC ATRI. Aisen has been a leading figure in Alzheimer’s disease research for more than two decades, having developed novel methodologies as well as designed and directed many large therapeutic trials. He received his B.A. in biochemistry and molecular biology from Harvard and his medical degree from Columbia. He completed his residency at Case Western Reserve University in Cleveland and Mount Sinai Medical Center in New York, and then fellowship training in rheumatology at New York University. After serving as chief medical resident at Mount Sinai, he began a solo practice in internal medicine and rheumatology in New York. Aisen joined the faculty of Mount Sinai in 1994 and was recruited to Georgetown University in 1999 as a professor of neurology and medicine. That year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers and designed and directed multicenter therapeutic trials. He became vice chair of the Department of Neurology at Georgetown in 2004. From 2007 through 2015, he was professor in the Department of Neurosciences at the University of California, San Diego and director of the Alzheimer’s Disease Cooperative Study.

Publications

. View in: PubMed

. View in: PubMed

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß. Alzheimers Dement. 2017 Sep; 13(9):1004-1012. View in: PubMed

The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. J Alzheimers Dis. 2017 Aug 21. View in: PubMed

Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2017 Aug 18; 60:92-103. View in: PubMed

On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther. 2017 Aug 09; 9(1):60. View in: PubMed

Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. BMC Med Genomics. 2017 May 24; 10(Suppl 1):29. View in: PubMed

Statistical properties of continuous composite scales and implications for drug development. J Biopharm Stat. 2017 Apr 12. View in: PubMed

Statistical properties of continuous composite scales and implications for drug development. J Biopharm Stat. 2017 Apr 12; 1-11. View in: PubMed

Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimers Dement. 2017 Mar 22. View in: PubMed

Association between tau deposition and antecedent amyloid-ß accumulation rates in normal and early symptomatic individuals. Brain. 2017 Mar 17. View in: PubMed

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated ß-amyloid. Alzheimers Dement. 2017 Feb 27. View in: PubMed

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation. 2017 Jan 03; 14(1):1. View in: PubMed

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA. 2017 06 13; 317(22):2305-2316. View in: PubMed

Cognitive and functional changes associated with Aß pathology and the progression to mild cognitive impairment. Neurobiol Aging. 2016 Dec; 48:172-181. View in: PubMed

Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther. 2016 Sep 20; 8:39. View in: PubMed

Cognitive and functional changes associated with Aß pathology and the progression to mild cognitive impairment. Neurobiol Aging. 2016 Aug 26; 48:172-181. View in: PubMed

Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. BMC Med Genomics. 2016 Aug 12; 9 Suppl 1:30. View in: PubMed

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016 Jun 30; 8:25. View in: PubMed

Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol. 2016 Jun 01; 73(6):721-32. View in: PubMed

Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol. 2016 Jun 1; 73(6):721-32. View in: PubMed

Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial. Neurology. 2016 May 31; 86(22):2071-6. View in: PubMed

Accelerating rates of cognitive decline and imaging markers associated with ß-amyloid pathology. Neurology. 2016 May 17; 86(20):1887-96. View in: PubMed

Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials. Alzheimers Dement. 2016 May; 12(5):598-603. View in: PubMed

Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement. 2016 May; 12(5):631-2. View in: PubMed

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar; 12(3):292-323. View in: PubMed

The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis. 2016 Mar; 3(1):8-12. View in: PubMed

Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. Am J Geriatr Psychiatry. 2016 Feb; 24(2):126-35. View in: PubMed

Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement. 2016 05; 12(5):631-2. View in: PubMed

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016; 8:25. View in: PubMed

Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. BMC Med Genomics. 2016; 9 Suppl 1:30. View in: PubMed

Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther. 2016; 8:39. View in: PubMed

CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2016 Jan; 12(1):56-61. View in: PubMed

APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement. 2015 Dec; 11(12):1417-1429. View in: PubMed

APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement. 2015 Dec; 11(12):1417-29. View in: PubMed

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20; 85(16):1383-91. View in: PubMed

The transitional association between ß-amyloid pathology and regional brain atrophy. Alzheimers Dement. 2015 Oct; 11(10):1171-9. View in: PubMed

GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain. 2015 Oct; 138(Pt 10):3076-88. View in: PubMed

Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. J Alzheimers Dis. 2015 Sep 24; 48 Suppl 1:S171-91. View in: PubMed

Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. Alzheimers Dement. 2015 Sep; 11(9):1080-9. View in: PubMed

Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimers Dement. 2015 Sep; 11(9):1069-79. View in: PubMed

Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015 Sep; 14(9):926-44. View in: PubMed

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. J Alzheimers Dis. 2015 Jul 9; 47(1):205-14. View in: PubMed

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimers Dement. 2015 Jul; 11(7):772-91. View in: PubMed

Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimers Dement. 2015 Jul; 11(7):734-9. View in: PubMed

The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. Alzheimers Dement. 2015 Jul; 11(7):823-31. View in: PubMed

2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2015 Jun; 11(6):e1-120. View in: PubMed

2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2015 Jun; 11(6):e1-e120. View in: PubMed

Predicting Reduction of Cerebrospinal Fluid ß-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurol. 2015 May 1; 72(5):554-60. View in: PubMed

Predicting Reduction of Cerebrospinal Fluid ß-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurol. 2015 May; 72(5):554-60. View in: PubMed

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol. 2015 May; 2(5):534-47. View in: PubMed

Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's disease cooperative study cognitive function instrument. JAMA Neurol. 2015 Apr 1; 72(4):446-54. View in: PubMed

Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015 Apr; 72(4):446-54. View in: PubMed

Advances in Alzheimer's disease drug development. BMC Med. 2015 Mar 25; 13:62. View in: PubMed

Brain structure and function as mediators of the effects of amyloid on memory. Neurology. 2015 Mar 17; 84(11):1136-44. View in: PubMed

Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol. 2015 Mar; 77(3):547-52. View in: PubMed

Peripheral and central effects of ?-secretase inhibition by semagacestat in Alzheimer's disease. Alzheimers Res Ther. 2015; 7(1):36. View in: PubMed

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Res Ther. 2015; 7(1):39. View in: PubMed

Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimers Res Ther. 2015; 7(1):43. View in: PubMed

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. J Alzheimers Dis. 2015; 47(1):205-14. View in: PubMed

Advances in Alzheimer's disease drug development. BMC Med. 2015; 13(1):62. View in: PubMed

Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. J Alzheimers Dis. 2015; 43(3):949-55. View in: PubMed

Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. J Alzheimers Dis. 2015 Jan 1; 43(3):949-55. View in: PubMed

Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother. 2015 Jan; 15(1):83-105. View in: PubMed

Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol Aging. 2015 Jan; 36(1):273-82. View in: PubMed

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Front Behav Neurosci. 2015; 9:239. View in: PubMed

2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. View in: PubMed

Estimating long-term multivariate progression from short-term data. Alzheimers Dement. 2014 Oct; 10(5 Suppl):S400-10. View in: PubMed

The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Dis Extra. 2014 Sep-Dec; 4(3):509-16. View in: PubMed

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014 Aug; 71(8):961-70. View in: PubMed

Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014 Jul 15; 83(3):253-60. View in: PubMed

Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2014 Jun; 10(3 Suppl):S226-35. View in: PubMed

Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. J Am Geriatr Soc. 2014 May; 62(5):985-8. View in: PubMed

Clinical trial of an inhibitor of RAGE-Aß interactions in Alzheimer disease. Neurology. 2014 Apr 29; 82(17):1536-42. View in: PubMed

Serum brain-derived neurotrophic factor and the risk for dementia. JAMA. 2014 Apr 23-30; 311(16):1684-5. View in: PubMed

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol. 2014 Apr 15; 88(4):426-49. View in: PubMed

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014 Apr 10; 370(15):1460. View in: PubMed

The A4 study: stopping AD before symptoms begin? Sci Transl Med. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19; 6(228):228fs13. View in: PubMed

Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2014 Mar; 29(2):159-65. View in: PubMed

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21. View in: PubMed

Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol. 2014 Jan 15; 14:12. View in: PubMed

Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol. 2014; 14:12. View in: PubMed

Association of plasma and cortical amyloid beta is modulated by APOE e4 status. Alzheimers Dement. 2014 Jan; 10(1):e9-e18. View in: PubMed

Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):E4502-9. View in: PubMed

Detecting When "Quality of Life" Has Been "Enhanced": Estimating Change in Quality of Life Ratings. Open J Philos. 2013 Nov 01; 3(4A):24-31. View in: PubMed

Semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Oct 24; 369(17):1661. View in: PubMed

Focal hemosiderin deposits and ß-amyloid load in the ADNI cohort. Alzheimers Dement. 2013 Oct; 9(5 Suppl):S116-23. View in: PubMed

Developing dementia prevention trials: baseline report of the Home-Based Assessment study. Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):356-62. View in: PubMed

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013 Sep; 9(5):e111-94. View in: PubMed

The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment. Am J Geriatr Psychiatry. 2013 Sep; 21(9):906-14. View in: PubMed

Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013 Aug; 74(2):199-208. View in: PubMed

A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50. View in: PubMed

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44. View in: PubMed

Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology. 2013 Jul; 27(4):391-401. View in: PubMed

Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov. 2013 Apr; 12(4):324. View in: PubMed

Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. Alzheimer Dis Assoc Disord. 2013 Apr-Jun; 27(2):174-81. View in: PubMed

Health-related resource use and costs in elderly adults with and without mild cognitive impairment. J Am Geriatr Soc. 2013 Mar; 61(3):396-402. View in: PubMed

Antioxidants for Alzheimer disease-reply. JAMA Neurol. 2013 Feb; 70(2):270-1. View in: PubMed

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb; 12(2):207-16. View in: PubMed

Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology. 2013 Jan 15; 80(3):282-8. View in: PubMed

The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci. 2013; 5:11. View in: PubMed

Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One. 2013; 8(7):e70269. View in: PubMed

Early indications of future cognitive decline: stable versus declining controls. PLoS One. 2013; 8(9):e74062. View in: PubMed

Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging Behav. 2012 Dec; 6(4):634-48. View in: PubMed

Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012 Oct 1; 2(10):975-984. View in: PubMed

Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012 Oct 01; 2(10):975-984. View in: PubMed

Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012 Oct; 72(4):578-86. View in: PubMed

Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov. 2012 Sep; 11(9):655-6. View in: PubMed

CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex. 2012 Sep; 22(9):1993-2004. View in: PubMed

Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30; 367(9):795-804. View in: PubMed

Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol. 2012 Jul; 69(7):901-5. View in: PubMed

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul; 8(4):261-71. View in: PubMed

Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012 Jul; 69(7):836-41. View in: PubMed

Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol. 2012 Jul; 69(7):856-67. View in: PubMed

Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm (Vienna). 2012 Jul; 119(7):843-50. View in: PubMed

Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm. 2012 Jul; 119(7):843-50. View in: PubMed

Amyloid-ß--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012 Jun; 69(6):709-13. View in: PubMed

Considerations in the design of clinical trials for cognitive aging. J Gerontol A Biol Sci Med Sci. 2012 Jun; 67(7):766-72. View in: PubMed

Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging. 2012 May; 33(5):845-55. View in: PubMed

Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years. Int J Geriatr Psychiatry. 2012 Apr; 27(4):355-63. View in: PubMed

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. View in: PubMed

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 6; 109(10):3985-90. View in: PubMed

Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. View in: PubMed

Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012 Mar; 69(3):368-72. View in: PubMed

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012 Feb; 8(1 Suppl):S1-68. View in: PubMed

Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov. 2012 09; 11(9):655-6. View in: PubMed

Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost". PLoS One. 2012; 7(2):e30019. View in: PubMed

Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011 Dec; 68(12):1526-35. View in: PubMed

Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol. 2011 Dec; 95(4):594-600. View in: PubMed

Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiol Aging. 2011 Dec; 32 Suppl 1:S64-6. View in: PubMed

Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobaol Aging. 2011 Dec; 32 Suppl 1:S64-6. View in: PubMed

Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol. 2011 Dec; 95(4):579-93. View in: PubMed

Testing the right target and right drug at the right stage. Sci Transl Med. 2011 Nov 30; 3(111):111cm33. View in: PubMed

Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011 Oct; 68(10):1257-66. View in: PubMed

Amyloid-ß associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011 Oct; 70(4):657-61. View in: PubMed

Factors affecting Aß plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011 Oct; 122(4):401-13. View in: PubMed

Impact of apolipoprotein E4-cerebrospinal fluid ß-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement. 2011 Sep; 7(5):514-20. View in: PubMed

Q&A: The Alzheimer's Disease Neuroimaging Initiative. BMC Med. 2011 Sep 01; 9:101. View in: PubMed

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. View in: PubMed

PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Jul-Sep; 25(3):206-12. View in: PubMed

AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. Alzheimers Dement. 2011 Jul; 7(4):e109-17. View in: PubMed

Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain. 2011 May; 134(Pt 5):1479-92. View in: PubMed

Commentary on "Biomarkers in Alzheimer's disease drug development. " Can't live without 'em. Alzheimers Dement. 2011 May; 7(3):e48-50. View in: PubMed

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May; 7(3):280-92. View in: PubMed

Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. View in: PubMed

Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimers Dement. 2011 Mar; 7(2):127-32. View in: PubMed

Transforming cerebrospinal fluid Aß42 measures into calculated Pittsburgh Compound B units of brain Aß amyloid. Alzheimers Dement. 2011 Mar; 7(2):133-41. View in: PubMed

Requiring an amyloid-ß1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2011 Mar; 7(2):245-6; author reply 247-9. View in: PubMed

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011 Feb; 7(1):102-11. View in: PubMed

A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PLoS One. 2011 Jan 17; 6(1):e16259. View in: PubMed

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011 Jan 06; 3(1):1. View in: PubMed

A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PLoS One. 2011; 6(1):e16259. View in: PubMed

A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease. J Alzheimers Dis. 2011; 24 Suppl 2:5-16. View in: PubMed

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011; 3(1):1. View in: PubMed

Q&A: The Alzheimer's Disease Neuroimaging Initiative. BMC Med. 2011; 9:101. View in: PubMed

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010 Nov 3; 304(17):1903-11. View in: PubMed

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010 Nov 03; 304(17):1903-11. View in: PubMed

Dependence as a unifying construct in defining Alzheimer's disease severity. Alzheimers Dement. 2010 Nov; 6(6):482-93. View in: PubMed

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010 Nov; 133(11):3336-48. View in: PubMed

Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement. 2010 Sep; 6(5):412-9. View in: PubMed

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging. 2010 Aug; 31(8):1340-54. View in: PubMed

3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010 Aug; 31(8):1284-303. View in: PubMed

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Jul-Sep; 24(3):269-77. View in: PubMed

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol. 2010 Jun; 223(2):334-46. View in: PubMed

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010 May; 6(3):230-8. View in: PubMed

Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010 May; 6(3):239-46. View in: PubMed

3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp. 2010 May; 31(5):786-97. View in: PubMed

The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010 May; 6(3):202-11. e7. View in: PubMed

NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord. 2010 Apr-Jun; 24(2):159-64. View in: PubMed

Therapeutics for cognitive aging. Ann N Y Acad Sci. 2010 Apr; 1191 Suppl 1:E1-15. View in: PubMed

Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010 Mar; 6(2):89-97. View in: PubMed

Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010 Mar; 67(3):308-16. View in: PubMed

What the CERAD Battery Can Tell Us about Executive Function as a Higher-Order Cognitive Faculty. Curr Gerontol Geriatr Res. 2010; 510614. View in: PubMed

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan; 9(1):119-28. View in: PubMed

MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population. Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):333-6. View in: PubMed

The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):315-8. View in: PubMed

No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease. Neurobiol Aging. 2009 Aug; 30(8):1327-8. View in: PubMed

Alzheimer's disease therapeutic research: the path forward. Alzheimers Res Ther. 2009 Jul 09; 1(1):2. View in: PubMed

Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry. Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry. 2009 Jun; 70(6):919-21. View in: PubMed

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009 Apr; 65(4):403-13. View in: PubMed

The net effect of alternative allocation ratios on recruitment time and trial cost. Clin Trials. 2009 Apr; 6(2):126-32. View in: PubMed

Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008. " Facilitating Alzheimer's disease drug development in the United States. Alzheimers Dement. 2009 Mar; 5(2):125-7. View in: PubMed

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92. View in: PubMed

Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009 Feb 19; 7:7. View in: PubMed

Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo. Neurosci Lett. 2009 Jan 23; 450(1):51-5. View in: PubMed

Alzheimer's disease therapeutic research: the path forward. Alzheimers Res Ther. 2009; 1(1):2. View in: PubMed

Applications of neuroimaging to disease-modification trials in Alzheimer's disease. Behav Neurol. 2009; 21(1):129-36. View in: PubMed

Methodological issues in primary prevention trials for neurodegenerative dementia. J Alzheimers Dis. 2009; 16(2):235-70. View in: PubMed

Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009; 7:7. View in: PubMed

Agreement in cognitive and clinical assessments in Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(4):344-52. View in: PubMed

Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009; 6(1-2):23-8. View in: PubMed

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008 Oct 15; 300(15):1774-83. View in: PubMed

Amyloid-based therapeutics: findings translated into novel treatments. CNS Spectr. 2008 Oct; 13(10 Suppl 16):36-8. View in: PubMed

Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase. Chem Biol Interact. 2008 Sep 25; 175(1-3):380-6. View in: PubMed

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008 Aug; 65(8):1031-8. View in: PubMed

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 Jul 19; 372(9634):207-15. View in: PubMed

Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008 Jun 24; 1216:92-103. View in: PubMed

Tarenflurbil: a shot on goal. Lancet Neurol. 2008 Jun; 7(6):468-9. View in: PubMed

Treatment for MCI: is the evidence sufficient? Neurology. Treatment for MCI: is the evidence sufficient? Neurology. 2008 May 27; 70(22):2020-1. View in: PubMed

A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May; 4(3):156-63. View in: PubMed

Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo. Neurosci Lett. 2008 Apr 25; 435(3):186-9. View in: PubMed

A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008 Apr; 325(1):146-53. View in: PubMed

Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr Alzheimer Res. 2008 Feb; 5(1):73-82. View in: PubMed

An update on huperzine A as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2008 Feb; 17(2):209-15. View in: PubMed

Leon Thal and the therapeutic age of Alzheimer's disease. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S4-6. View in: PubMed

The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis Assoc Disord. The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis Assoc Disord. 2008 Jan-Mar; 22(1):4-5. View in: PubMed

An aspirin a day for Alzheimer's disease? Lancet Neurol. An aspirin a day for Alzheimer's disease? Lancet Neurol. 2008 Jan; 7(1):20-1. View in: PubMed

Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur J Neurosci. 2007 Nov; 26(9):2458-68. View in: PubMed

Commentary on "The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006. "--an appraisal. Alzheimers Dement. 2007 Oct; 3(4):446-8. View in: PubMed

Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. 2007 Sep; 4(4):473-8. View in: PubMed

Antibody against C-terminal Abeta selectively elevates plasma Abeta. Neuroreport. 2007 Feb 12; 18(3):293-6. View in: PubMed

A simple method to rule out dementia with temporal orientation. Alzheimers Dement. 2007 Jan; 3(1):28-32. View in: PubMed

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci. 2007; 31(2):165-70. View in: PubMed

BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J Neurochem. 2006 Dec; 99(6):1555-63. View in: PubMed

ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI). Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S170-8. View in: PubMed

Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials". Alzheimers Dement. 2006 Oct; 2(4):272-4. View in: PubMed

Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach. Alzheimers Dement. 2006 Oct; 2(4):303-13. View in: PubMed

ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S109-23. View in: PubMed

Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed. Alzheimers Dement. 2006 Jul; 2(3):153-4. View in: PubMed

Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem Biol Interact. 2005 Dec 15; 157-158:239-46. View in: PubMed

Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? Nat Clin Pract Neurol. Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? Nat Clin Pract Neurol. 2005 Nov; 1(1):20-1. View in: PubMed

One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline. Am J Alzheimers Dis Other Demen. 2005 Jul-Aug; 20(4):239-47. View in: PubMed

An Abeta sequestration approach using non-antibody Abeta binding agents. Curr Alzheimer Res. 2005 Apr; 2(2):265-8. View in: PubMed

Pharmacologic treatment options in Alzheimer's disease: optimizing disease management. J Am Acad Nurse Pract. 2005 Mar; Suppl:5-7. View in: PubMed

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005; 11(4):353-68. View in: PubMed

The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. CNS Drugs. 2005; 19(12):989-96. View in: PubMed

Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly. Neuroepidemiology. 2005; 24(1-2):110-6. View in: PubMed

Inflammatory processes and Alzheimer's disease. Expert Rev Neurother. 2004 Sep; 4(5):793-8. View in: PubMed

Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun. 2004 Jul 02; 319(3):733-7. View in: PubMed

Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun. 2004 Jul 2; 319(3):733-7. View in: PubMed

Georgetown University School of Medicine. Acad Med. 2004 Jul; 79(7 Suppl):S45-50. View in: PubMed

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66. View in: PubMed

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 Jun 04; 289(21):2819-26. View in: PubMed

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 Jun 4; 289(21):2819-26. View in: PubMed

NSAIDs and hypertension. Arch Intern Med. 2003 May 12; 163(9):1115; author reply 1115-6. View in: PubMed

A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):246-9. View in: PubMed

The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002 Sep; 1(5):279-84. View in: PubMed

Anti-inflammatory agents in Alzheimer's disease. Curr Neurol Neurosci Rep. 2002 Sep; 2(5):405-9. View in: PubMed

Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging. 2002 May-Jun; 23(3):327-34. View in: PubMed

Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J Pain Symptom Manage. 2002 Apr; 23(4 Suppl):S35-40. View in: PubMed

Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol. 2002 Feb; 103(2):157-62. View in: PubMed

Informatics and Geriatric Psychiatry. Am J Geriatr Psychiatry. 1996 Spring; 4(2):140-151. View in: PubMed

Determinants of Length of Stay in Geropsychiatry. Am J Geriatr Psychiatry. 1994 Spring; 2(2):165-168. View in: PubMed

Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer's Disease. Am J Geriatr Psychiatry. 1993 Summer; 1(3):244-248. View in: PubMed

Trazodone for Behavioral Disturbance in Alzheimer's Disease. Am J Geriatr Psychiatry. 1993 Autumn; 1(4):349-350. View in: PubMed

Powered bySC CTSI